サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1611113

強皮症治療の市場規模、シェア、動向分析レポート：薬剤クラス別、適応症別、地域別、セグメント別予測、2025年～2030年

Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 70 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
強皮症治療の市場規模、シェア、動向分析レポート：薬剤クラス別、適応症別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年11月14日
発行: Grand View Research
ページ情報: 英文 70 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

強皮症治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、強皮症治療の世界市場規模は2025～2030年にかけてCAGR 5.0％を記録し、2030年までに34億4,000万米ドルに達すると予測されています。

市場成長の背景には、ブランド薬、ジェネリック医薬品、市販医薬品を含む低分子治療など、適応外で使用される様々な治療が利用可能になったことがあります。

複数の適応症と薬剤クラスが混在しているため、市場は複数の参入企業によってセグメント化されています。Rocheは、生物製剤の免疫抑制剤、アクテムラ/ロアクテムラ、セルセプト、リツキサンなどで圧倒的なシェアを占めています。PfizerとEli Lillyが同市場の主要企業です。予測期間中、Boehringer Ingelheim、Corbus Pharmaceuticals、Fibrocellを含む新規参入企業が、この市場における既存企業のシェアをわずかに奪うと考えられます。

強皮症治療市場は開発段階にあります。効能追加承認は市場参入企業が採用する最も一般的な戦略のひとつです。例えば、Bayerのリオシグアトは、以前はPAHに使用されていたが、現在はSScに関連した趾潰瘍の治療として臨床検査中です。この戦略は製薬産業にとって有利であり、高い開発コストを相殺し、すでに開発され市場に存在する1つの分子からより大きな利益を得ることができるため、他の製薬企業もこれに追随しています。

強皮症治療市場レポートハイライト

  • 免疫抑制剤セグメントは2024年に27.4%の最大シェアを占め、予測期間を通じて優位性を維持する可能性が高いです。
  • この薬剤クラスに関連する有利な償還シナリオにより、免疫抑制剤への高い嗜好性が市場シェアの優位性を支えています。
  • 全身性強皮症の適応症が主要な市場シェアを占めており、高価格の免疫抑制剤の使用によりさらに拡大するとみられます。
  • 2024年の北米強皮症治療市場では、米国市場が90.6%のシェアを占めています。強皮症治療市場の継続的な成長を支えているのは、希少疾病用医薬品に対する償還状況の進展と相まって、期待される適応拡大やファーストインクラスの治療の発売です。
  • 強皮症の適応外治療にジェネリック医薬品やバイオシミラーが多く使用されていることが主要原因です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 強皮症治療市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析

第4章 強皮症治療市場：薬剤クラスのビジネス分析

  • 薬剤クラス市場シェア、2024年と2030年
  • 薬剤クラスセグメントダッシュボード
  • 市場規模と予測と動向分析、薬剤クラス別、2018～2030年
  • 免疫抑制剤
  • ホスホジエステラーゼ5阻害剤-PHA
  • エンドセリン受容体拮抗薬
  • プロスタサイクリン類似体
  • カルシウムチャネル遮断薬
  • 鎮痛剤
  • カルシウムチャネル遮断薬
  • その他

第5章 強皮症治療市場：適応症のビジネス分析

  • 適応症市場シェア、2024年と2030年
  • 適応症セグメントダッシュボード
  • 市場規模と予測と動向分析、適応症別、2018～2030年
  • 全身性強皮症
  • 局所性強皮症

第6章 強皮症治療市場：薬剤クラスによる地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模と予測動向分析、2018～2030年
  • 北米
    • 国別、2018～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • 国別、2018～2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • F. Hoffman La-Roche Ltd
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Emerald Health Pharmaceuticals
    • Sanofi
    • Cytori Therapeutics Inc.
    • Chemomab
    • Corbus Pharmaceuticals Holdings, Inc.
    • Calliditas Therapeutics AB
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global scleroderma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 6 North America scleroderma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 North America scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 9 U.S. scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 U.S. scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Canada scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Canada scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Mexico scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Mexico scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Europe scleroderma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Europe scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 18 UK scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 UK scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 20 Germany scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Germany scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 22 France scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 France scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Italy scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Italy scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Spain scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Spain scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Denmark scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Denmark scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Sweden scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 Sweden scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 32 Norway scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Norway scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific scleroderma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 37 Japan scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Japan scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 39 China scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 China scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 41 India scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 India scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 43 Australia scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Australia scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 45 South Korea scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 South Korea scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Thailand scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Thailand scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Latin America scleroderma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Latin America scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 52 Brazil scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Brazil scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Argentina scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Argentina scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Scleroderma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 59 South Africa scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 South Africa scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 63 UAE scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 UAE scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 65 Kuwait scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Scleroderma therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market snapshot
  • Fig. 8 Drug class and indication outlook (USD Million)
  • Fig. 9 Competitive landscape
  • Fig. 10 Scleroderma therapeutics market dynamics
  • Fig. 11 Scleroderma therapeutics market: Porter's five forces analysis
  • Fig. 12 Scleroderma therapeutics market: PESTLE analysis
  • Fig. 13 Scleroderma therapeutics market: Drug class segment dashboard
  • Fig. 14 Scleroderma therapeutics market: Drug class market share analysis, 2024 & 2030
  • Fig. 15 Immunosuppressors market, 2018 - 2030 (USD Million)
  • Fig. 16 Phosphodiesterase 5 inhibitors - PHA market, 2018 - 2030 (USD Million)
  • Fig. 17 Endothelin receptor antagonists market, 2018 - 2030 (USD Million)
  • Fig. 18 Prostacyclin analogues market, 2018 - 2030 (USD Million)
  • Fig. 19 Calcium channel blockers market, 2018 - 2030 (USD Million)
  • Fig. 20 Analgesics market, 2018 - 2030 (USD Million)
  • Fig. 21 Others market, 2018 - 2030 (USD Million)
  • Fig. 22 Scleroderma therapeutics market: Indication segment dashboard
  • Fig. 23 Scleroderma therapeutics market: Indication market share analysis, 2024 & 2030
  • Fig. 24 Systemic scleroderma market, 2018 - 2030 (USD Million)
  • Fig. 25 Morphea market, 2018 - 2030 (USD Million)
  • Fig. 26 Linear market, 2018 - 2030 (USD Million)
  • Fig. 27 Localized scleroderma market, 2018 - 2030 (USD Million)
  • Fig. 28 Diffuse systemic sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 29 Limited cutaneous systemic sclerosis syndrome market, 2018 - 2030 (USD Million)
  • Fig. 30 Scleroderma therapeutics market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 France country dynamics
  • Fig. 46 France scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 55 Norway country dynamics
  • Fig. 56 Norway scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 China country dynamics
  • Fig. 61 China scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 62 India country dynamics
  • Fig. 63 India scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 70 Latin America scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 75 MEA scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework
目次
Product Code: GVR-3-68038-219-8

Scleroderma Therapeutics Market Growth & Trends:

The global scleroderma therapeutics market size is expected to reach USD 3.44 billion by 2030, registering a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is credited to the availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.

The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly to the company's share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.

The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting high development costs and in reaping larger benefits from one molecule already developed and present in the market.

Scleroderma Therapeutics Market Report Highlights:

  • The immunosuppressors segment accounted for the largest share of 27.4% in 2024, and is likely to maintain the dominance throughout the forecast years
  • High preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class supports its dominant market share
  • Systemic scleroderma indication segment accounted for the major market share and will expand further due to use of high-priced immunosuppressants
  • The U.S. market accounted for 90.6% share of the North America scleroderma therapeutics market in 2024. Expected label expansions and expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs support continual scleroderma therapeutics market growth
  • Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Scleroderma Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Scleroderma Therapeutics Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Immunosuppressors
    • 4.4.1. Immunosuppressors Market, 2018 - 2030 (USD Million)
  • 4.5. Phosphodiesterase 5 inhibitors - PHA
    • 4.5.1. Phosphodiesterase 5 inhibitors - PHA Market, 2018 - 2030 (USD Million)
  • 4.6. Endothelin Receptor Antagonists
    • 4.6.1. Endothelin Receptor Antagonists Market, 2018 - 2030 (USD Million)
  • 4.7. Prostacyclin Analogues
    • 4.7.1. Prostacyclin Analogues Market, 2018 - 2030 (USD Million)
  • 4.8. Calcium Channel Blockers
    • 4.8.1. Calcium Channel Blockers Market, 2018 - 2030 (USD Million)
  • 4.9. Analgesics
    • 4.9.1. Analgesics Market, 2018 - 2030 (USD Million)
  • 4.10. Calcium Channel Blockers
    • 4.10.1. Calcium Channel Blockers Market, 2018 - 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Scleroderma Therapeutics Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Systemic Scleroderma
    • 5.4.1. Systemic Scleroderma Market, 2018 - 2030 (USD Million)
    • 5.4.2. Morphea
      • 5.4.2.1. Morphea Market, 2018 - 2030 (USD Million)
    • 5.4.3. Linear
      • 5.4.3.1. Linear Market, 2018 - 2030 (USD Million)
  • 5.5. Localized Scleroderma
    • 5.5.1. Localized Scleroderma Market, 2018 - 2030 (USD Million)
    • 5.5.2. Diffuse Systemic Sclerosis
      • 5.5.2.1. Diffuse systemic sclerosis market, 2018 - 2030 (USD Million)
    • 5.5.3. Limited Cutaneous Systemic Sclerosis Syndrome
      • 5.5.3.1. Limited cutaneous systemic sclerosis syndrome market, 2018 - 2030 (USD Million)

Chapter 6. Scleroderma Therapeutics Market: Regional Estimates & Trend Analysis by Drug Class and Indication

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Sweden Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Norway Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Australia Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. South Korea Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Scleroderma therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. F. Hoffman La-Roche Ltd
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Bristol-Myers Squibb Company
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Bayer AG
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Boehringer Ingelheim International GmbH
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Emerald Health Pharmaceuticals
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Sanofi
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Cytori Therapeutics Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Chemomab
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Corbus Pharmaceuticals Holdings, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Calliditas Therapeutics AB
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives